- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Serum Institute to supply Inactivated Polio Vaccine to Centre for Universal Immunisation Programme
The IPV of SII is World Health Organisation pre-qualified for supplies to various countries worldwide also.
New Delhi: Serum Institute of India (SII) will start supplying Inactivated Polio Vaccine (IPV) to the Union government for the Universal Immunisation Programme from this month, becoming the first indigenous company to do so, official sources said on Tuesday.
The Union Health Ministry has recently placed a purchase order with SII for 54 lakh doses of IPV vaccine. So far, the government was dependent on Sanofi, a foreign pharmaceutical company for supplying IPV to the universal immunisation programme.
"I wish to inform you that our firm, Serum Institute of India has become the first Indian manufacturer to supply Inactivated Poliomyelitis Vaccine (IPV) to MoHFW which will protect children of our country from Poliomyelitis disease," Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII communicated to the Health Ministry recently.
The IPV of SII is World Health Organisation pre-qualified for supplies to various countries worldwide also. The Union Health Ministry has also placed an order with Sanofi for the supply of 36 lakh doses of IPV.
"It is a matter of pride for all of us that in addition to many other life-saving vaccines as well as COVID-19 vaccines, our country is now ''Atmanirbar'' (self-reliant) for Inactivated Poliomyelitis Vaccine (IPV) also and we are moving ahead on the lines of the clarion call of our Prime Minister ''ATMANIRBHAR BHARAT''," Singh said in his letter.
The first lot of IPV will be supplied to GMSD (Government Medical Stores Depot) this month shortly for the vaccination programme as per the requirement of the Health Ministry.
"The supply of IPV from first Indian company i.e. Serum Institute of India has become possible because of your kind guidance, support of Team MoHFW, farsighted vision of our CEO, Dr Adar C Poonawalla along with relentless efforts of team SIIPL during COVID-19 pandemic," Singh stated in the communication.
India was officially declared polio-free in 2014, but the immunisation programme continues in the country.
IPV has been introduced in the Universal Immunisation Programme as part of the Global Polio end-game strategy, to mitigate the risk associated with the trivalent oral polio vaccine to bivalent oral polio vaccine switch.
IPV was introduced in November 2015 initially in six states, which was expanded across the country by April 2016.
Read also: Covid-19: Aspen Pharmacare eyes Serum Institute model as it seeks licence to make JnJ vaccine
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751